Common arthritis drug stopped Alzheimer's in its tracks, researchers say

Share this article:

An arthritis drug stopped the deterioration of cognitive functions and activities of daily living capabilities in Alzheimer's patients in a small trial, researchers from the University of Southampton in England recently announced.

The study involved 41 people with mild to moderate Alzheimer's, according to information released by the University of Southampton. Some were given the arthritis drug Etanercept every week for six months, and some received a placebo.

Those who took the medication did not deteriorate in terms of cognition or behavior over the six months, while those in the other group did experience declines, the investigators found.

“Our results are better than we expected,” stated lead researcher Clive Holmes, Ph.D.

While the study was small and lasted only a short time, “our projections suggest the benefits would continue,” Holmes added. He called for further trials.

Etanercept blocks a blood protein released as part of an inflammatory response. High levels of the protein have been associated with worsening Alzheimer's, the researchers noted.

Holmes presented the findings at the Alzheimer's Association International Conference, held last week in Copenhagen.

Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.